Stockreport

Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technol...

HCA Healthcare, Inc.  (HCA) 
Last hca healthcare, inc. earnings: 4/21 08:30 am Check Earnings Report
US:NYSE Investor Relations: investor.hcahealthcare.com
PDF First demonstration that CAR T cells enhanced with anti-exhaustion technology can both expand and infiltrate into solid tumors No significant safety signal related to [Read more]